Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Apyx Medical (APYX) over the last 11 years, with Q3 2025 value amounting to $1.2 million.

  • Apyx Medical's Non-Current Deffered Revenue fell 432.73% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 432.73%. This contributed to the annual value of $1.1 million for FY2024, which is 1027.29% down from last year.
  • Apyx Medical's Non-Current Deffered Revenue amounted to $1.2 million in Q3 2025, which was down 432.73% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Apyx Medical's Non-Current Deffered Revenue registered a high of $1.4 million during Q4 2022, and its lowest value of $855000.0 during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $1.2 million (2023), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Apyx Medical's Non-Current Deffered Revenue surged by 11304.35% in 2021, and later tumbled by 1150.57% in 2023.
  • Over the past 5 years, Apyx Medical's Non-Current Deffered Revenue (Quarter) stood at $1.3 million in 2021, then rose by 6.42% to $1.4 million in 2022, then fell by 11.51% to $1.2 million in 2023, then dropped by 10.27% to $1.1 million in 2024, then grew by 8.77% to $1.2 million in 2025.
  • Its Non-Current Deffered Revenue was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.